

PHARMACEUTICAL 2023

MANNKIND CORP Rank 369 of 446









PHARMACEUTICAL 2023

mannkind

MANNKIND CORP Rank 369 of 446

The relative strengths and weaknesses of MANNKIND CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MANNKIND CORP compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 39% points. The greatest weakness of MANNKIND CORP is the variable Other Liabilities, reducing the Economic Capital Ratio by 189% points.

The company's Economic Capital Ratio, given in the ranking table, is -123%, being 166% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	234,896
Cost of Goods Sold	16,003
Intangible Assets	3,581
Liabilities, Current	67,296
Liabilities, Non-Current	43,027
Other Assets	11,679
Other Compr. Net Income	0
Other Expenses	90,436
Other Liabilities	435,497
Other Net Income	-23,290
Other Revenues	99,770
Property and Equipment	45,126
Research and Development	19,721
Selling, General and Administrative Expense	37,720

Output Variable	Value in 1000 USD
Assets	295,282
Liabilities	545,820
Expenses	163,880
Revenues	99,770
Stockholders Equity	-250,538
Net Income	-87,400
Comprehensive Net Income	-87,400
Economic Capital Ratio	-123%

